|
Sep 27
|
Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
|
|
Jul 12
|
Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors
|
|
Apr 27
|
Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023
|
|
Apr 24
|
Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab
|